Title : Relative Risk of Peripheral Neuropathy With Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Cancers: A Systematic Review and Meta-Analysis.

Pub. Date : 2021 May 27

PMID : 34194883






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ado-trastuzumab emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate, consisting of trastuzumab and a microtubule inhibitor DM1, which has been approved for HER2-positive breast cancer. Maytansine erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Ado-trastuzumab emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate, consisting of trastuzumab and a microtubule inhibitor DM1, which has been approved for HER2-positive breast cancer. Maytansine erb-b2 receptor tyrosine kinase 2 Homo sapiens